YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Randomized Phase II Trial of Chemoembolization and Sorafenib

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma

Interventions: Drug: conventional TACE in combination with sorafenib, administered on a continuous schedule
Drug: conventional TACE in combination with sorafenib, administered on a sequential schedule

First Posted Date: 2016-09-20

Last Posted Date: 2018-01-10

Lead Sponsor: Yale University

Registration Number: NCT02908165

Locations: 🇺🇸
Smilow Cancer Center, New Haven, Connecticut, United States

Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status

Not Applicable

Completed

Conditions: Sepsis
Hypotension

Interventions: Other: Point of Care Ultrasound

First Posted Date: 2016-09-20

Last Posted Date: 2020-01-13

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT02907931

Locations: 🇺🇸
John B. Pierce Laboratory, New Haven, Connecticut, United States

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

Completed

Conditions: Ductal Carcinoma In Situ

Interventions: Procedure: Sentinel lymph node biopsy (SLNB)

First Posted Date: 2016-09-20

Last Posted Date: 2019-05-15

Lead Sponsor: Yale University

Target Recruit Count: 28291

Registration Number: NCT02908178

Locations: 🇺🇸
SEER-Medicare Dataset, Bethesda, Maryland, United States

Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation

Not Applicable

Completed

Conditions: Substance-related Disorders

Interventions: Behavioral: Implementation Facilitation

First Posted Date: 2016-09-20

Last Posted Date: 2023-05-08

Lead Sponsor: Yale University

Target Recruit Count: 3838

Registration Number: NCT02907944

Locations: 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸
Immunology Center at Miriam Hospital, Providence, Rhode Island, United States
🇺🇸
Haelen Center at Yale New Haven Hospital, New Haven, Connecticut, United States

and more 1 locations

A Reinforcement Approach to Increase Use of CGM

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Behavioral: Reinforcement for wearing CGM

First Posted Date: 2016-09-20

Last Posted Date: 2020-08-31

Lead Sponsor: Yale University

Target Recruit Count: 19

Registration Number: NCT02907346

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Capnography At the Bedside: Leading Educational Efforts

Not Applicable

Completed

Conditions: Emergency

Interventions: Other: Policy Change
Behavioral: Education and Reminder Posters

First Posted Date: 2016-09-15

Last Posted Date: 2018-08-22

Lead Sponsor: Yale University

Target Recruit Count: 902

Registration Number: NCT02901197

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Endometrial Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-09-14

Last Posted Date: 2024-04-08

Lead Sponsor: Yale University

Target Recruit Count: 25

Registration Number: NCT02899793

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Optimizing Tobacco Dependence Treatment in the Emergency Department

Phase 3

Completed

Conditions: Tobacco Use Disorder

Interventions: Other: SmokefreeText (Text)
Behavioral: Brief Negotiated Interview (BNI)
Drug: Nicotine replacement therapy (NRT)
Other: CT Smokers Quitline (QL)

First Posted Date: 2016-09-12

Last Posted Date: 2020-12-04

Lead Sponsor: Yale University

Target Recruit Count: 1056

Registration Number: NCT02896400

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Pembrolizumab in HNSCC With Residual Disease After Radiation

Phase 2

Terminated

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-09-08

Last Posted Date: 2023-12-28

Lead Sponsor: Yale University

Target Recruit Count: 9

Registration Number: NCT02892201

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
University of Texas Southwestern Medical Center (UTSW), Dallas, Texas, United States

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Phase 1

Withdrawn

Conditions: Relapsed and Refractory Aggressive B- and T-cell Lymphomas
Lymphoma

Interventions: Drug: volasertib
Drug: belinostat

First Posted Date: 2016-08-22

Last Posted Date: 2017-12-22

Lead Sponsor: Yale University

Registration Number: NCT02875002

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Massey Cancer Center, Richmond, Virginia, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy